中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

136 records (took 0.03 seconds)

    IGF-1 fusion polypeptides and therapeutic uses thereof
    3.
    发明授权
    IGF-1 fusion polypeptides and therapeutic uses thereof 有权
    IGF-1融合多肽及其治疗用途

    公开(公告)号：US08445434B2

    公开(公告)日：2013-05-21

    申请号：US13416481

    申请日：2012-03-09

    Applicant: David J. Glass ,  George D. Yancopoulos ,  Thomas J. Daly ,  Nicholas J. Papadopoulos

    Inventor： David J. Glass ,  George D. Yancopoulos ,  Thomas J. Daly ,  Nicholas J. Papadopoulos

    IPC: A61K39/395 ,  A61P3/10

    CPC classification number: C07K14/65 ,  A61K38/30 ,  C07K2319/00 ,  C07K2319/30 ,  C07K2319/75

    Abstract: A fusion protein comprising at least one IGF1 variant component and a fusion component (F), and, optionally, a signal sequence, exhibits improved stability relative to the native IGF1 or IGF2 polypeptide. The fusion component (F) may be a multimerizing component, such as an immunoglobulin domain, in particular, the Fc domain of IgG or a heavy chain of IgG. IGF1 variants were shown to have improved ability to increase muscle mass in a subject suffering from muscle atrophy caused by cachexia, immobilization, aging, chronic disease, cancer, hereditary condition, an atrophy-causing agent, and the like. IGF1 variants are also effective in decreasing blood glucose in a subject suffering from diabetes or hyperglycemia.

    Abstract translation: 包含至少一种IGF1变体组分和融合组分（F）以及任选的信号序列的融合蛋白相对于天然IGF1或IGF2多肽表现出改进的稳定性。 融合组分（F）可以是多聚化组分，例如免疫球蛋白结构域，特别是IgG的Fc结构域或IgG的重链。 IGF1变体显示具有改善的能力，以增加受到恶病质，固定化，老化，慢性疾病，癌症，遗传性疾病，引起萎缩症等引起的肌肉萎缩的受试者的肌肉质量的增加。 IGF1变体在降低患有糖尿病或高血糖症的受试者中的血糖中也是有效的。

    METHODS OF USING IL-1 ANTAGONISTS TO TREAT FAMILIAL MEDITERRANEAN FEVER (FMF)
    4.
    发明申请
    METHODS OF USING IL-1 ANTAGONISTS TO TREAT FAMILIAL MEDITERRANEAN FEVER (FMF) 审中-公开
    使用IL-1拮抗剂治疗家族中性粒细胞（FMF）的方法

    公开(公告)号：US20110311537A1

    公开(公告)日：2011-12-22

    申请号：US13222759

    申请日：2011-08-31

    Applicant: SCOTT MELLIS ,  MARGARET KAROW ,  GEORGE D. YANCOPOULOS ,  JOANNE PAPADOPOULOS

    Inventor： SCOTT MELLIS ,  MARGARET KAROW ,  GEORGE D. YANCOPOULOS ,  JOANNE PAPADOPOULOS

    IPC: A61K39/395 ,  A61P29/00

    CPC classification number: C07K14/7155 ,  A61K38/00 ,  A61K38/177 ,  A61K45/06 ,  A61K2300/00

    Abstract: Methods of treating, inhibiting, or ameliorating Familial Mediterranean Fever (FMF) by administering to a subject in need thereof a therapeutically effective amount of an interleukin 1 (IL-1) antagonist, are provided. The IL-1 antagonist can be an antibody or derivative thereof, which is capable of blocking or inhibiting the biological action of IL-1, thereby treating, inhibiting or ameliorating FMF. Also provided are methods of treating, inhibiting, or ameliorating FMF by administering a therapeutically effective amount of an IL-1 antagonist in combination with additional therapeutic agents, including IL-1-specific fusion proteins, TNF inhibitors, NSAIDs, steroids, and the like.

    Abstract translation: 提供了通过向有需要的受试者施用治疗有效量的白细胞介素1（IL-1）拮抗剂来治疗，抑制或改善家族性地中海热（FMF）的方法。 IL-1拮抗剂可以是抗体或其衍生物，其能够阻断或抑制IL-1的生物学作用，从而治疗，抑制或改善FMF。 还提供了通过将治疗有效量的IL-1拮抗剂与另外的治疗剂（包括IL-1特异性融合蛋白，TNF抑制剂，NSAID，类固醇等）组合施用来治疗，抑制或改善FMF的方法 。

    Methods of Using IL-1 Antagonists to Treat Autoinflammatory Disease
    7.
    发明申请
    Methods of Using IL-1 Antagonists to Treat Autoinflammatory Disease 审中-公开
    使用IL-1拮抗剂治疗自身炎症性疾病的方法

    公开(公告)号：US20090156492A1

    公开(公告)日：2009-06-18

    申请号：US12259366

    申请日：2008-10-28

    Applicant: Scott Mellis ,  Margaret Karow ,  George D. Yancopoulos ,  Joanne Papadopoulos

    Inventor： Scott Mellis ,  Margaret Karow ,  George D. Yancopoulos ,  Joanne Papadopoulos

    IPC: A61K38/17 ,  A61P29/00

    CPC classification number: C07K14/7155 ,  A61K38/00 ,  A61K38/177 ,  A61K45/06 ,  A61K2300/00

    Abstract: Methods of treating, inhibiting, or ameliorating an autoinflammatory disorder, disease, or condition in a subject in need thereof, comprising administering to a subject in need a therapeutic amount of an interleukin 1 (IL-1) antagonist, wherein the autoinflammatory disorder, disease, or condition is treated, inhibited, or ameliorated. The IL-1 antagonist is an IL-1 trap, preferably comprising a sequence selected from the group consisting of SEQ ID NO: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, or a substantially identical having at least 95% identity to the sequence shown in SEQ ID NO: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 and capable of binding and inhibiting IL-1. The therapeutic methods are useful for treating a human adult or child suffering from Neonatal Onset Multisystem Inflammatory Disorder (NOMID/CINCA), Muckle-Wells Syndrome (MWS), Familial Cold Autoinflammatory Syndrome (FCAS), familial mediterranean fever (FMF), or systemic onset juvenile rheumatoid arthritis (Still's Disease).

    Abstract translation: 在有需要的受试者中治疗，抑制或改善自身炎性疾病，疾病或病症的方法，包括向需要治疗的受试者施用治疗量的白细胞介素1（IL-1）拮抗剂，其中所述自身炎性疾病，疾病 ，或条件得到治疗，抑制或改善。 IL-1拮抗剂是IL-1捕获物，优选包含选自SEQ ID NO：4,6,8,10,12,14,16,18,20,22,24,26， 或与SEQ ID NO：4,6,8,10,12,14,16,18,20,22,24,26中所示的序列具有至少95％的同一性，并能够结合和抑制IL- 1。 治疗方法可用于治疗患有新生儿起始多系统炎症性疾病（NOMID / CINCA），Muckle-Wells综合征（MWS），家族性冷自身炎症综合征（FCAS），家族性地中海热（FMF）或全身性 发病青少年类风湿关节炎（Still氏病）。

    Methods of treating diseases with a VEGF antagonist
    8.
    发明授权
    Methods of treating diseases with a VEGF antagonist 有权
    用VEGF拮抗剂治疗疾病的方法

    公开(公告)号：US07531172B2

    公开(公告)日：2009-05-12

    申请号：US11502736

    申请日：2006-08-11

    Applicant: Neil Stahl ,  George D. Yancopoulos ,  Eric Furfine ,  Jesse M. Cedarbaum

    Inventor： Neil Stahl ,  George D. Yancopoulos ,  Eric Furfine ,  Jesse M. Cedarbaum

    IPC: A61K38/18 ,  C07K14/71 ,  C12N15/62

    CPC classification number: A61K38/179

    Abstract: A method of reducing or preventing hypertension associated with administration of a vascular endothelial growth factor (VEGF) antagonist in a human subjects suffering from a disease or condition treatable with a VEGF antagonist in which is it desirable to reduce or prevent hypertension. The method is particularly useful for treatment of patients unresponsive to treatment with a VEGF inhibitor administered intravenously.

    Abstract translation: 在患有可用VEGF拮抗剂治疗的疾病或病症的人类受试者中降低或预防与血管内皮生长因子（VEGF）拮抗剂的给药相关的高血压的方法，其中希望减少或预防高血压。 该方法对于治疗对用静脉内施用的VEGF抑制剂治疗无反应的患者特别有用。

Patent Agency Ranking